Fennec Pharmaceuticals (FENC) Q2 2025: PEDMARK Drives 33% Growth as AYA Adoption Accelerates

2025-08-14 | By EarningsIQ Research

PEDMARK, Fennec’s flagship therapy for cisplatin-induced hearing loss, delivered a third straight quarter of double-digit growth, underpinned by expanding adoption in adolescent and young adult (AYA) oncology practices. Strategic execution is translating into both new account wins and deeper penetration within existing centers, while European and Japanese market opportunities are on the horizon. Investors should watch for milestone triggers and operational leverage as commercial investments moderate in the second half.

Summary

• AYA Market Penetration: PEDMARK adoption is gaining traction in large community oncology networks, expanding the addressable patient base.
• Commercial Model Validation: Repeat customer growth and formulary wins validate the targeted sales approach and patient support model.
• Global Expansion Levers: European partnership and Japan data readout set up additional catalysts for late 2025 and 2026.

Performance Analysis

Fennec’s Q2 2025 results highlight a business in the midst of a commercial inflection, with PEDMARK, the only FDA-approved therapy for cisplatin-induced ototoxicity (CIO), driving a 33% year-over-year revenue increase and 10% sequential growth. This marks the third consecutive quarter of sequential sales growth, reflecting disciplined execution and increasing awareness of the long-term impact of CIO among oncology care teams. PEDMARK’s core market has expanded beyond pediatrics into the much larger AYA segment, where management estimates 20,000 annual cisplatin-treated patients, roughly 10 times the pediatric opportunity.

Commercial momentum is evidenced by the addition of 14 new accounts, including major community oncology networks, and a growing mix of repeat customers as initial users expand prescribing. Retention within activated centers is emerging as a key growth driver, with practices expanding PEDMARK use after positive initial outcomes. European royalties from Norgine remain nascent but are expected to scale as launches progress across the UK, Germany, and broader EU5 markets. Operating expenses rose in the quarter due to stepped-up marketing and headcount, but management reiterated full-year expense discipline as commercial investments normalize in the second half.

• Account Expansion: Growth is increasingly driven by deeper penetration within existing centers, not just new wins.
• Cost Seasonality: Cash operating expenses peaked in the first half, with reductions expected going forward.
• International Upside: Early European traction and upcoming Japan data create multi-region catalysts.

Fennec’s revenue trajectory is now supported by both new formulary access and repeat business, setting up a path to operating leverage as expense growth moderates.

Executive Commentary

Strategic Positioning

1. AYA Market Penetration

The largest near-term lever for Fennec remains the AYA segment, which is estimated at 20,000 cisplatin-treated patients annually. Recent formulary wins at major community oncology networks have expanded PEDMARK’s reach, and management notes that initial use in a center often leads to broader adoption as clinicians gain experience and see positive patient outcomes. This “land and expand” dynamic is accelerating as repeat prescribing grows within activated accounts.

2. Standard of Care Momentum

Clinical alignment is building around PEDMARK’s role as the standard of care for CIO prevention, as evidenced by the recent ENCODA Positive Quality Intervention (PQI) endorsement. This peer-reviewed guidance provides practical protocols for oncology care teams, lowering barriers to adoption and reinforcing the product’s differentiation as the only FDA- and EMA-approved therapy for this indication. The PQI is expected to drive further institutional adoption and support payer access.

3. Multidisciplinary Engagement

Fennec’s commercial strategy increasingly targets the full spectrum of stakeholders—from oncologists and pharmacists to ENTs and audiologists—reflecting the multidisciplinary nature of cancer survivorship and quality of life. This approach is expanding the funnel of advocates for PEDMARK and supporting both patient and provider education efforts, especially as the company leverages advocacy organizations and patient assistance programs like Fennec HEERS.

4. Global Expansion and Partnerships

International growth is emerging as a secondary pillar, with European launches via Norgine gaining traction in the UK and Germany, and additional EU5 and Nordic launches expected in the coming quarters. Japanese market entry is contingent on upcoming clinical data, with management signaling a partner-led regulatory strategy and strong local investigator enthusiasm. Both regions offer milestone and royalty upside, with Germany pricing a near-term trigger for a material payment.

Key Considerations

Fennec’s Q2 demonstrates that commercial discipline and strategic targeting are translating into tangible growth, but the next phase will test the scalability and durability of this model as the company balances U.S. expansion with international opportunities.

Key Considerations:

• Repeat Prescriber Growth: The shift toward higher repeat customer mix signals sticky adoption and validates the product’s clinical value.
• Formulary and PQI Wins: Institutional endorsements and practical guidance documents are lowering adoption friction and supporting broader payer coverage.
• Expense Discipline Commitment: Management expects cash operating expenses to decline in the second half, preserving cash and enabling a path to profitability.
• Milestone and Royalty Catalysts: European launches, final Germany pricing, and upcoming Japan data represent potential inflection points for non-U.S. revenue streams.
• Compounded Product Substitution Risk: FDA guidance and targeted messaging remain crucial to defending market share, especially in pediatric academic centers.

Risks

Key risks include the pace of AYA and institutional adoption, potential pushback from payers or formulary committees, and delays in international launches or milestone triggers. Compounded product substitution, particularly in academic pediatric centers, remains a threat, though less so in the AYA community setting. Expense reductions may lag if commercial investments need to be sustained longer than anticipated.

Forward Outlook

For Q3 2025, Fennec expects:

• Continued sequential revenue growth as additional accounts within major oncology networks activate PEDMARK.
• Expense moderation as commercial and marketing investments wind down in the second half.

For full-year 2025, management reiterated guidance for:

• Cash operating expenses in line with 2024 levels (approximately $33 million).

Management highlighted three near-term drivers:

• Scaling U.S. account activation and repeat prescribing in both pediatric and AYA populations.
• European royalty and milestone contributions as Norgine expands launches and secures final pricing in Germany.
• Japan study readout and potential partnership monetization in Q4 2025.

Takeaways

Fennec’s commercial execution is translating into sustained revenue growth, with the AYA segment emerging as a key long-term growth engine. Expense discipline and operational leverage will be critical to achieving cash profitability, especially as international catalysts approach. Investors should monitor milestone timing, formulary expansion, and the mix of new versus repeat customers to gauge durability of the growth trajectory.

• AYA Adoption Inflection: Expansion in large community oncology networks is unlocking a much larger patient pool, with initial use setting the stage for broader account penetration.
• Expense Leverage on Horizon: Commercial investments are front-loaded, with management guiding to lower cash burn in the second half as revenue scales.
• Upcoming Catalysts: European milestone payments, Japan data, and further U.S. account wins will determine the next leg of upside.

Conclusion

Fennec’s Q2 2025 results showcase a business successfully executing on its commercial transformation, with PEDMARK adoption broadening across both new and existing accounts. As U.S. growth compounds and international levers come into play, the company is positioned for operating leverage and potential milestone-driven upside in the coming quarters.

Industry Read-Through

Fennec’s success in driving adoption of a differentiated, single-indication therapy through targeted education and institutional engagement offers a playbook for other specialty pharma companies seeking to establish new standards of care in underpenetrated markets. The importance of multidisciplinary buy-in, practical clinical guidance (such as PQI), and payer alignment is reinforced. European and Japanese market entry dynamics, including the timing of pricing and regulatory approvals, will be instructive for peers with global expansion ambitions. The ongoing battle against compounded product substitution also highlights the value of regulatory clarity and advocacy in preserving branded market share.

FENC Healthcare Pharmaceuticals Specialty Pharma PEDMARK Oncology AYA International Expansion